Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Mabelio (ceftobiprole medocaril) in patients with CSF devices
2016-003917-83Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Sep 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceftobiprole medocaril in bacterial meningitis and ventriculitis, sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoints: Plasma pharmacokinetics of ceftobiprole and CSF pharmacokinetics of ceftobiprole. Started Sep 2017; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
bacterial meningitisventriculitis
Beyond the preview
Go deeper on 2016-003917-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003917-83.